NCT02317393View on ClinicalTrials.gov

Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Non-seminomatous Germ Cell TumorsMetastasis
Interventions
OTHER

K5-RGD PET

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

OTHER

FDG

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

Trial Locations (5)

14000

CHU, Caen

14076

Centre François Baclesse, Caen

Unknown

Centre Henri Becquerel, Rouen

CHU Rouen, Rouen

Institut Claudius Regaud, Toulouse

All Listed Sponsors
lead

Centre Francois Baclesse

OTHER

NCT02317393 - Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy | Biotech Hunter | Biotech Hunter